Kyowa Hakko Kogyo Co., Ltd.

Kyowa Hakko Kogyo Kabushiki Kaisha

Other

Kyowa Hakko Kogyo K.k.

Kyowa Hakko Kogyo Kabushiki

Tadashi Ashizawa

Makoto Morimoto

Masaji Kasai

Motomichi Kono

Yutaka Kanda

Hiromitsu Saito

Katsushige Gomi

Hitoshi Arai

Yutaka Saito

Akira Sato

Kunikatsu Shirahata

Hirofumi Nakano

Chikara Murakata

Tadashi Hirata

Keiichi Takahashi

Yoichi Uosaki

Tokuyuki Kuroda

Shingo Kakita

Hiroshi Sano

Hiroyuki Yamaguchi

Yoshinori Yamashita

Akira Asai

Tamio Mizukami

Tatsuya Tamaoki

Fusao Tomita

Toru Yasuzawa

Shun-ichi Ikeda

Kozo Asano

Shigeo Katsumata

Akira Mihara

Yasushi Shida

Koji Hisamura

Yutaka Ohsawa

Tohru Sugaya

Hideo Ueno

Yasuhiro Suzuki

Yutaka Saitoh

Shiro Akinaga

Katsuhiko Ando

Isao Kawamoto

Keiko Ochiai

Masami Okabe

Shigeru Chiba

Isami Takahashi

Ikuo Matsukuma

Shinzo Ishii

Mitsunobu Hara

Youichi Uosaki

Soichiro Sato

Yukiteru Mimura

Tatsuhiro Ogawa

Harumi Ogawa

Yuichi Takahashi

Yuko Arai

Kazuhisa Fujimoto

Katsunori Kita

Michio Ichimura

Jun Eishima

Junji Kanazawa

Uichiro Kimura

Ritsuko Katahira

Kenichi Muroi

Toshiaki Iwasaki

Rieko Tanaka

Kazuyo Sugiyama

Shun-Ichi Ikeda

Kimihito Sasaki

Etsuko Nukui

2-piperidone compounds

DC107 derivatives represented by formula (I) or pharmaceutically acceptable salts thereof which have antimicrobial activity and antitumor activity are provided: ##STR1## wherein R.sup.1 represents CO(CR.sup.4A R.sup.4B).sub.n1 (O(CH.sub.2).sub.p1).sub.n2 OR.sup.5 {wherein n1 represents an integer of 1 or 2; R.sup.4A and R.sup.4B are the same or different, and each represents hydrogen or lower alkyl; p1 and n2 each represents an integer of 1 to 10; and R.sup.5 represents hydrogen, lower alkyl, or the like), or ##STR2##

DC107 derivatives

DC107 derivatives represented by formula (I) or pharmaceutically acceptable salts thereof which have antimicrobial activity and antitumor activity are provided: ##STR1## wherein R.sup.1 represents hydrogen, lower alkoxyalkyl, aralkyloxyalkyl, lower alkoxyalkoxyalkyl, lower alkoxyalkoxyalkoxyalkyl, aralkyl, tetrahydropyranyl, COR.sup.4, or the like; R.sup.2 represents hydrogen or COR.sup.6 ; R.sup.3 represents --CH.sub.2 OCOR.sup.7, phthalimidomethyl, or the like; and W represents oxygen or NR.sup.8 (wherein R.sup.8 represents hydroxy, lower alkoxy, lower alkenyloxy, aralkyloxy, substituted or unsubstituted arylsulfonylamino, or lower alkoxycarbonylamino).

UCT1072 compounds

The present invention relates to propenone derivatives represented by the following formula (I): ##STR1## wherein R.sup.1 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, or YR.sup.5 (wherein Y represents S or O; and R.sup.5 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a substituted or unsubstituted cyclic ether residue); R.sup.2 and R.sup.3 independently represent hydrogen, lower alkyl, or substituted or unsubstituted aralkyl, or alternatively R.sup.2 and R.sup.3 are combined to form substituted or unsubstituted methylene or ethylene; R.sup.4 represents hydrogen, hydroxy, lower alkyl, substituted or unsubstituted aralkyl, lower alkoxy, substituted or unsubstituted aralkyloxy, or halogen; and X represents substituted or unsubstituted indolyl; or pharmaceutically acceptable salts thereof.

Propenone derivatives

DC 107 derivatives and treatment methods

UCH15 compounds

Compound UCH9

Novel mitomycin derivatives represented by the formula (I) are obtained by introducing a substituent at the 6-position. The mitomycin derivatives of the present invention have an antitumor activity.

6-ethyl mitomycin derivatives

Mitomycin derivatives

Disclosed is pyrazoloacridone derivatives represented by formula (I): ##STR1## wherein: each of R.sup.1a, R.sup.1b, R.sup.1c and R.sup.1d independently represents hydrogen, lower alkyl, --(CH.sub.2).sub.p --X wherein p represents an integer of 1 to 6, and X represents hydroxy, lower alkoxy or --NR.sup.2a R.sup.2b wherein each of R.sup.2a and R.sup.2b independently represents hydrogen, lower alkyl, or --(CH.sub.2).sub.m --Y wherein m represents an integer of 1 to 6, and Y represents hydroxy, lower alkoxy or --NR.sup.3a R.sup.3b wherein each of R.sup.3a and R.sup.3b independently represents hydrogen or lower alkyl

Pyrazoloacridone derivatives

Disclosed are mitomycin derivatives of formula (I): ##STR1## where W represents halogen; X represents methoxy, amino or ethylenimino; Y represents hydrogen or methyl; Z represents hydrogen or methyl; and one of R.sup.1 and R.sup.2 represents carbamoyloxymethyl, and the other represents hydrogen. The derivatives are usable as an antitumor and antibacterial agent.

Halogen substituted mitomycin derivatives

Disclosed in a mitomycin derivative represented by the formula (I): ##STR1## wherein W is a heterocyclic group.

Novel DC-89 compounds represented by the general formula: ##STR1## wherein X represents a single bond or --CH.sub.2 --; and when X represents a single bond, Y represents --CH.sub.2 Br or --CH.sub.2 Cl and when X represents --CH.sub.2 --, Y represents Br, are obtained by the present invention. The compounds have antibacterial and anti-tumor activity.

DC-89 compounds and process for their preparation

Disclosed are DC-52 derivatives represented by the formula: ##STR1## wherein each of R.sup.1 and R.sup.2 independently represents hydrogen or hydroxyl, X represents hydroxyl and Y represents cyano and Z represents carboxyl or hydroxymethyl, or pharmacologically acceptable salts thereof. The DC-52 derivatives are useful as antitumor agents.

DC-52 derivatives

Growing community of inventors

Numazu, Japan

Tadashi Ashizawa